Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition in which falling estrogen levels cause changes in the vulva, vagina, urethra and bladder. Typical symptoms are vaginal dryness, burning, painful sex, urgency and recurrent urinary infections. Unlike hot flushes, GSM usually does not resolve with time, but moisturizers, lubricants and low-dose vaginal estrogen are effective and generally safe.
What is genitourinary syndrome of menopause?
In 2014, the International Society for the Study of Women's Sexual Health and the North American Menopause Society (now The Menopause Society) introduced the term genitourinary syndrome of menopause to replace older terms such as vulvovaginal atrophy and atrophic vaginitis. The new name reflects that the condition affects not only the vagina but also the vulva, urethra and bladder, and that it is a medical condition rather than simply "ageing".
The tissues of the lower genital and urinary tract are rich in estrogen receptors. When estrogen declines, the vaginal lining becomes thinner, paler, less elastic and less lubricated. Blood flow decreases, the vaginal pH rises, and the protective lactobacilli that normally dominate the vaginal flora decline. These changes make the tissues more fragile and more prone to irritation and infection.
How common is GSM?
GSM affects a large proportion of postmenopausal women, and estimates in published studies commonly range around half or more. Yet many women never discuss it with a clinician, either because they assume it is a normal part of ageing or because they feel embarrassed. Unlike vasomotor symptoms, which often ease over several years, GSM tends to worsen without treatment.
What are the symptoms?
Symptoms vary widely in type and severity. They fall into three main groups.
Genital symptoms
- Vaginal dryness and reduced natural lubrication
- Burning, itching or irritation of the vulva and vagina
- Light bleeding or spotting after intercourse
- Changes in discharge and a feeling of tightness or narrowing
Sexual symptoms
- Pain during penetration (dyspareunia)
- Reduced arousal, sensation or orgasm
- Avoidance of intimacy because of discomfort
Urinary symptoms
- Urgency and frequency
- Burning on urination without infection
- Recurrent urinary tract infections
Who is at risk?
Any woman with low estrogen can develop GSM, and symptoms may begin during perimenopause, years before the final period. Besides natural menopause, it is common after surgical removal of the ovaries, during treatment with aromatase inhibitors or other anti-estrogen therapies for breast cancer, after pelvic radiotherapy or chemotherapy, and with some medications that suppress ovarian function. Breastfeeding women can experience similar, temporary changes. Smoking, lack of sexual activity and never having had a vaginal birth have been associated with more pronounced symptoms in some studies.
How is GSM diagnosed?
Diagnosis is mainly clinical, based on symptoms and examination. A clinician will typically:
- Ask about genital, sexual and urinary symptoms and how much they affect daily life.
- Review medications, cancer history and contraception or hormone therapy.
- Examine the vulva and vagina for pallor, dryness, loss of folds, fragility, narrowing and redness.
- Measure vaginal pH if helpful, since a higher pH supports the diagnosis.
- Exclude other conditions such as infections, lichen sclerosus, dermatitis or, with bleeding, endometrial problems.
- Test urine when urinary symptoms are present to exclude infection.
What are the treatment options?
Treatment is guided by symptom severity, personal preference and medical history. Position statements from The Menopause Society recommend a stepwise approach.
Non-hormonal first steps
Water-based or silicone-based lubricants reduce friction during sex. Regular vaginal moisturizers, used several times a week independent of sexual activity, help maintain hydration. Avoiding irritants such as perfumed washes and douching also matters.
Product choice makes a difference. Some lubricants and moisturizers have a very high osmolality or contain glycerin, fragrances, warming agents or parabens that can irritate fragile tissue. Plain, fragrance-free products designed for vaginal use are usually better tolerated, and silicone-based lubricants last longer during intercourse. If a product stings, stop using it and try another formulation.
Low-dose vaginal estrogen
For moderate to severe symptoms, or when lubricants are not enough, low-dose vaginal estrogen is highly effective. It comes as creams, tablets, inserts or a ring. A Cochrane review found vaginal estrogen preparations effective compared with placebo for relieving symptoms. Because systemic absorption is low, it is considered safe for most women, and current guidance indicates that a progestogen is generally not needed to protect the uterus with low-dose vaginal products.
Other prescription options
Vaginal DHEA (prasterone) and the oral selective estrogen receptor modulator ospemifene are approved in some countries for painful intercourse due to menopause. Systemic hormone therapy can help GSM in women who also need treatment for hot flushes, though vaginal treatment may still be required.
Supportive therapies
Pelvic floor physiotherapy and vaginal dilators can help when pain has led to muscle guarding or narrowing. Regular sexual activity or vaginal stimulation may help maintain tissue elasticity and blood flow. Combining treatments, for example vaginal estrogen with a lubricant and physiotherapy, is common and often more effective than any single measure.
What about laser and energy-based devices?
Fractional CO2 and erbium lasers have been promoted for GSM. Some trials show improvement, but results have been mixed, and at least one randomized trial comparing laser with sham treatment found no significant difference in symptom outcomes. Long-term safety and benefit remain uncertain, and the U.S. FDA issued a warning in 2018 about marketing of energy-based devices for vaginal conditions. Professional societies currently regard these devices as investigational for GSM rather than as a replacement for proven therapies.
GSM after breast cancer
Women with a history of breast cancer, especially those taking aromatase inhibitors, often have severe symptoms. Non-hormonal treatments are tried first. If they fail, low-dose vaginal estrogen may be considered after discussion with the oncology team, weighing quality of life against the theoretical risk. ACOG guidance supports individualized shared decision-making in this group.
Frequently asked questions
Will GSM go away on its own?
Usually not. Unlike hot flushes, GSM tends to persist or worsen without treatment, so ongoing therapy is often needed to maintain comfort.
Is vaginal estrogen safe long term?
Low-dose vaginal estrogen has minimal absorption into the bloodstream and has a reassuring safety profile in available studies. Any postmenopausal bleeding should still be reported and investigated.
Can GSM cause bladder infections?
Yes. Changes in vaginal pH and flora can increase the risk of recurrent urinary tract infections, and vaginal estrogen can reduce recurrences in postmenopausal women.
How long does vaginal estrogen take to work?
Many women notice improvement within a few weeks, with maximum benefit after about two to three months of regular use.
Do I need treatment if I am not sexually active?
Yes, if you have symptoms. Dryness, irritation and urinary problems can affect comfort and health regardless of sexual activity.
References
- Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause, 2014.
- The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement. Menopause, 2020.
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews, 2016.
- American College of Obstetricians and Gynecologists. Clinical Consensus No. 2: Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer. 2021.
- U.S. Food and Drug Administration. Statement on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation." 2018.
This article is for general education and does not replace an examination by a qualified gynecologist. Individual results vary, and every procedure carries risks.
